SANDOZ Group AG, the SIX Swiss Exchange-listed global leader in generic and biosimilar medicines, has appointed Christine Chong as its country head for Malaysia, Singapore and Brunei.
Chong brings more than a decade of leadership experience in the pharmaceutical industry across Southeast Asia, India, Hong Kong and Taiwan where she has led business transformation, portfolio growth and organisational development.
Consistently driving market expansion, digital innovation and employee engagement, her proven track record spans commercial excellence, product launches and business turnarounds, thus making her a valuable addition to the Sandoz leadership team.
“I’m truly honoured to join Sandoz and look forward to working with our talented teams across Malaysia, Singapore and Brunei to advance our mission of pioneering access for patients,” enthused Chong who is a Malaysian by nationality.
“Together, we ‘ll continue to innovate, grow and make a meaningful impact in the healthcare landscape.”
Sandoz Asia Cluster president Boon Huey Ee credited Chong for bringing deep experience across diverse markets and a strong focus on improving patient access.
“Under her leadership, Sandoz will continue to expand its impact and deliver on our commitment to patients across the region,” he envisages.
In 2026, Sandoz marks 140 years of heritage, 80 years of antibiotics leadership and 20 years of pioneering biosimilars globally, alongside 55 years of presence in Malaysia and 40 years in Singapore. – May 6, 2026
Main image credit: People Matters
